Pipex Pharmaceuticals to Host Conference Call at 10:15am ET Wednesday July 9th to Discuss Phase II Clinical Trial Results in Dry Age-Related Macular Degeneration (AMD) With Oral Z-Monocys
Published: Jul 09, 2008
ANN ARBOR, MI--(Marketwire - July 08, 2008) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous systems and autoimmune diseases, today announced that it will hold a conference call on Wednesday, July 9, 2008 at 10:15 a.m. ET to discuss the results of its double-blind, placebo-controlled phase II clinical trial results in the treatment of dry age-related macular degeneration (AMD) with oral Z-Monocys. Nicholas Stergis, Vice Chairman and Chief Executive Officer of Pipex, will host the call.